MRC Prion Unit at UCL, Institute of Prion Diseases
Update on PRN100: an anti-prion protein monoclonal antibody developed by the MRC Prion Unit for treatment of human prion diseases including Creutzfeldt-Jakob disease (CJD)
University College London Hospitals NHS Foundation Trust (UCLH) will be treating a patient with the antibody after the Court of Protection confirmed on 8th October 2018 that it is lawful and in the patient's best interests to receive the treatment. A statement and Q&A giving more details are available on the UCLH website at http://www.uclh.nhs.uk/News/Pages/PrionCJD.aspx
We pursue a long-term research strategy with a mission to develop diagnostic tests and treatments for these incurable disorders through an understanding of their fundamental biology.
In addition to its research mission, the Institute of Prion Diseases is dedicated to training skilled researchers, committed to advancing and disseminating knowledge and technology to improve the quality of life and economic competitiveness of the UK and promote dialogue with the public, politicians, the media and other stakeholders about medical research.
The Institute is closely linked to the NHS National Prion Clinic (NPC) - a national referral centre for prion diseases, based at the National Hospital for Neurology and Neurosurgery (part of UCLH NHS Foundation Trust). The partnership and integration that exists between the Institute and NPC provides a unique environment for training, developing treatments and expertise in this area of medicine as well as supporting neurodegenerative disease research more widely.